Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 20/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31245156 | 0.93 | TIPARP (0.52) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245017 | 0.90 | TIPARP (0.53) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245270 | 0.88 | TIPARP (0.55) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245408 | 0.88 | TIPARP (0.65) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245472 | 0.86 | TIPARP (0.52) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245102 | 0.86 | TIPARP (0.52) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31244907 | 0.86 | TIPARP (0.52) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245228 | 0.80 | TIPARP (0.54) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL31245392 | 0.79 | TIPARP (0.49) | TIPARPCYP2C9CYP2C19PARP2PARP1 | |
| SCHEMBL31245374 | 0.79 | TIPARP (0.52) | TIPARPCYP2C9CYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | TIPARP 92/4885CYP2C9 1795/4885CYP2C19 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.